TIDMYGEN
Yourgene Health PLC
18 May 2021
Yourgene Health plc
("Yourgene" or the "Group" or the "Company")
Launch of IONA (R) Care NIPT service offering
Extended clinical menu to screen SCAs and AAs for pregnant
women
Manchester, UK - 18 May 2021: Yourgene (AIM: YGEN), the
international molecular diagnostics group, announces the launch of
IONA (R) Care, a non-invasive prenatal test (NIPT) service
offering, with an extended clinical menu measuring the likelihood
that a pregnant woman is carrying a fetus with sex chromosome
aneuploidies (SCA(1) ) and autosomal aneuploidies (AA(2) ), in
addition to the current IONA(R) test which offers screening for
trisomies 21, 18 and 13 and fetal sex determination.
The IONA (R) Care test is carried out on a small maternal blood
sample and is performed using the CE-marked IONA(R) Nx NIPT
workflow, that utilises next generation sequencing (NGS), at the
Company's Manchester Citylabs 1.0 via Yourgene Genomics Services.
This additional clinical menu is now available as a service
offering, primarily aimed at the private clinic testing market
primarily in the UK, but also with customers in the Middle East and
Turkey. It provides a competitive high quality offering due to the
fast turnaround time, enabling some results to be turned around in
as fast as two days, with more than 80% of patients receiving
results within three days.
This week, Yourgene is running a series of webinars aimed at
existing healthcare professionals on the IONA (R) Care test to
educate them on the extended clinical offering which can be
presented to pregnant mothers. In addition, we will be inviting new
customers to join our webinars to learn more about how IONA (R)
Care can give a competitive service for clinics and healthcare
providers looking to expand their NIPT offering.
Lyn Rees, CEO of Yourgene Health, commented: "We are thrilled to
launch IONA (R) Care, an extension of our IONA advanced prenatal
screening service, which builds on the reliability and accuracy of
our in-house NIPT service offering, providing pregnant women with
more choice. The enhanced clinical offering is optional, enabling
the Company to be more competitive within the NIPT market and we
look forward to updating shareholders on our progress."
(1) - Sex chromosome aneuploidies (SCA) occur when there are
changes in the expected number of chromosomes associated with sex
determination, the X and Y Chromosome
(2) - Autosomal aneuploidies (AA) refers to all the additional
trisomies (the presence of an extra chromosome) or monosomies
(having a single chromosome instead of a pair)
Yourgene Health plc Tel: +44 (0)161 669 8122
Lyn Rees, Chief Executive Officer investors@yourgene-health.com
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing
Tel: +44 (0)20 7496 3000
N+1 Singer (Joint Corporate Broker)
Aubrey Powell / Tom Salvesen / George
Tzimas
Stifel Nicolaus Europe Limited (Joint Tel: +44 (0)20 7710 7600
Corporate Broker)
Nicholas Moore / Matthew Blawat / Ben
Maddison
Walbrook PR Ltd (Media and Investor Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
Relations)
Paul McManus / Lianne Cawthorne Mob: 07980 541 893 / Mob: 07584 391 303
About Yourgene Health
Yourgene Health is an international molecular diagnostics group
which develops and commercialises genetic products and services.
The group works in partnership with global leaders in DNA
technology to advance diagnostic science.
Yourgene primarily develops, manufactures, and commercialises
simple and accurate molecular diagnostic solutions, for
reproductive health, precision medicine and now infectious
diseases. The Group's flagship products include non-invasive
prenatal tests (NIPT) for Down's Syndrome and other genetic
disorders, Cystic Fibrosis screening tests, invasive rapid
aneuploidy tests, and a recent extension into the oncology space
with DPYD genotyping.
The launch of Yourgene Genomic Services has enabled Yourgene to
offer a global laboratory service network equipped to be a full
life-cycle partner for clinical, research and pharmaceutical
organisations to support partners at the preclinical, clinical, and
post-market stages to develop, manufacture, obtain regulatory
approval and commercialise new products and services. In addition,
Yourgene Genomic Services offers an NIPT and high throughput COVID
testing service.
In August 2020, Yourgene acquired Coastal Genomics, Inc., a
sample preparation technology company based in Vancouver, Canada,
enabling the Company to extend its offering and IP portfolio in the
DNA sample preparation sector. The acquisition increased Yourgene's
geographical penetration into the US and Canada, supplementing
existing coverage in the UK, Europe, MEA and Asia.
Yourgene Health is headquartered in Manchester, UK with offices
in Taipei, Singapore, the US and Canada, and is listed on the
London Stock Exchange's AIM market under the ticker "YGEN". For
more information visit www.yourgene-health.com and follow us on
twitter @Yourgene_Health.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAARMMTMTABTPB
(END) Dow Jones Newswires
May 18, 2021 02:00 ET (06:00 GMT)
Premaitha (LSE:NIPT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Premaitha (LSE:NIPT)
Historical Stock Chart
From Sep 2023 to Sep 2024